Cell Therapy

Intrauterine administration of hCG-activated peripheral blood mononuclear cells for Female Infertility

N/A
Waitlist Available
Research Sponsored by Fertilys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upafter 48 hours of culture
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing whether giving extra immune cells to people with fertility issues can help them get pregnant and carry to term.

Eligible Conditions
  • Female Infertility

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 48 hours of culture
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 48 hours of culture for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical pregnancy rate
Embryo implantation rate (biochemical pregnancy)
Secondary outcome measures
Cytokines (LIF, IL-6, IL-10, TNFα, FGF-2, VEGF, IL-8) quantification by ELISA in PBMC culture medium at Day 2
Peripheral blood mononuclear cells populations (PBMC) distribution at Day 0
Peripheral blood mononuclear cells populations distribution at Day 2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Recurrent miscarriageExperimental Treatment1 Intervention
Group II: Recurrent implantation failuresExperimental Treatment1 Intervention
Group III: No recurrent implantation failureActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intrauterine administration of hCG-activated peripheral blood mononuclear cells
2017
N/A
~430

Find a site

Who is running the clinical trial?

FertilysLead Sponsor
3 Previous Clinical Trials
675 Total Patients Enrolled
Centre hospitalier de l'Université de Montréal (CHUM)OTHER
352 Previous Clinical Trials
127,448 Total Patients Enrolled

Media Library

Intrauterine administration of hCG-activated peripheral blood mononuclear cells (Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04753736 — N/A
Female Infertility Research Study Groups: Recurrent implantation failures, Recurrent miscarriage, No recurrent implantation failure
Female Infertility Clinical Trial 2023: Intrauterine administration of hCG-activated peripheral blood mononuclear cells Highlights & Side Effects. Trial Name: NCT04753736 — N/A
Intrauterine administration of hCG-activated peripheral blood mononuclear cells (Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04753736 — N/A
Female Infertility Patient Testimony for trial: Trial Name: NCT04753736 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still slots available for participants in this experiment?

"The latest information on clinicaltrials.gov states that this trial, which was initially posted in September of 2021, is no longer seeking participants at the current time. However, there are still 245 other trials actively enrolling patients."

Answered by AI

Who else is applying?

What state do they live in?
California
Virginia
Pennsylvania
Other
How old are they?
18 - 65
What site did they apply to?
Fertilys
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
3+
2

Why did patients apply to this trial?

I've been trying to have an IVF but it seems that all is fine but I have repeated implantation failures.
Patient
~0 spots leftby Sep 2024